Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Institute Council of Research AdvocatesAgency NameDepartment of Health and Human Services
Fiscal Year2019Committee Number5248
Original Establishment Date8/17/1998Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/ncra/ncra.htm
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*16
Current Charter Date8/17/2018Designated Fed Officer Position Title*ACTING DIRECTOR, OFFICE OF ADVOCACY RELATIONS
Date Of Renewal Charter8/17/2020Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*AMY
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*WILLIAMS
Establishment Authority*Authorized by LawDesignated Federal Officer Suffix
Specific Establishment Authority*42 U.S.C. 285a-2(b)(7)Designated Federal Officer Phone*240-781-3406
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-541-4517
Committee Type*ContinuingDesignated Federal Officer Email*williaam@mail.nih.gov
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The role the National Cancer Institute’s Council of Research Advocates (NCRA) is to identify and respond to issues and challenges facing the Institute and the cancer research community, at the request of the NCI Director. Board members provide informed, non-scientific perspectives relevant to promoting research outcomes that are in the best interest of patients. This includes identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI or other federal government decisions or actions, as well as enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders, in the interest of meeting common Institute and community goals. In FY2019, NCRA held three in-person meetings on October 19, 2018, May 20, 2019, and September 9, 2019. Members were provided an update on budget, legislative, and clinical research activities before providing their thoughts, insights, and observations to the NCI Director.
How is membership balanced?*The Committee consists of up to 16 members, including the Chair appointed by the Director, NCI. The membership consists of cancer research advocates who are involved in the cancer experience and possess an expert understanding of non-scientific burdens to cancer research as well as of the perspectives and dynamics of the research, patient, policy, and advocacy communities interested in cancer research and cancer care delivery. This expert understanding will have been gained through experience working in the cancer advocacy field, affiliation with a cancer related professional society, affiliation with a research foundation involved in cancer research or healthcare, experience as a health care professional focused on the study of cancer and other related diseases, or experience serving as a thought-leader in an area related to cancer research and care delivery.
How frequent & relevant are cmte mtgs?*Meetings of the full Committee will be held approximately 2-3 times within a fiscal year. The Committee met three times during this reporting period to advise and make recommendations to the Director, NCI, from the perspective and viewpoint of cancer research advocates on a wide variety of issues, programs and research priorities. In FY2019, the NCRA meeting was held on October 19, 2018, May 20, 2019, and September 9, 2019 (in-person).
Why advice can't be obtained elsewhere?*The membership consists of cancer research advocates who possess an expert understanding of non-scientific burdens related to cancer research, as well as of the perspectives and dynamics of the research, patient, policy, and advocacy communities interested in cancer research and cancer care delivery. The advice is not available from NCI staff or existing committees.
Why close or partially close meetings?N/A
Recommendation RemarksReports: This committee did not produce any public reports.

Members: The terms for David Arons, Gregory Aune, Mary Ann Battles, Shelly Fuld Nasso, Martha Gaines, June McKoy, Senaida Poole (Fernandez), and Regina Vidaver have been administratively extended. As such, their term of service end dates are different than what was reported on the FY18 ACR.

Meetings: The committee had three meetings in FY19.

Costs: The increase in operating costs for FY19 are due to a increase in the number of meetings held in FY19. The reduction in Federal Staff costs is due to staffing changes.

Recommendations: The FY19 meetings focused on NCI clinical research initiatives and served to educate NCRA members on these major activities, as well as provide an opportunity for members to interact with the NCI Director. Thus, no recommendations were made in FY19.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*NoAction Reorganize Priorities*No
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchNoAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentThe Committee makes recommendations to federal staff by responding to issues and challenges facing the Institute and cancer research community and provides advice to the NCI Director around approaches to enhance community input, optimize community outreach, and promote effective collaborations that will help address these challenges and lead to improved research outcomes. As a result, specific topics of interest to the cancer research advocacy community are defined and integrated into the NCI’s Office of Advocacy Relations communications strategy and plan.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherYesNumber Of Grants Reviewed0
Outcome CommentPublic engagement in the research process.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNCI supports basic, translational and clinical research which often takes many years to deliver clinically applicable scientific advances.Grants Review CommentN/A
Number Of Recommendations*93Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe NCRA is an advisory committee designed to provide perspective, feedback, and ideas to the NCI. NCRA also provides a forum for government and private groups to work together to address critical issues that affect NCI’s work. No recommendations were made in FY19.Access Agency WebsiteYes
% of Recs Fully Implemented*40.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe percentage of recommendations implemented as stated above were developed at the time the Annual Comprehensive Report was prepared.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*40.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe percentage of recommendations implemented as stated above were developed at the time the Annual Comprehensive Report was prepared.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the NCRA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at http://deainfo.nci.nih.gov/advisory/ncra/ncra.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the NCRA meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback CommentE-mail updates and presentations at the meetings. NCI leadership gave feedback directly to the NCRA through meetings with the full advisory group. The NCI community is made aware of NCRA activities through NCI’s Office of Advocacy Relations.Narrative Description*The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. The NCI Council of Research Advocates (NCRA), is the only federal advisory committee comprised of advocate leaders at NCI. NCRA members are chosen for their expert knowledge of issues of importance to the cancer research community. The NCRA identifies and responds to issues and challenges facing the Institute and cancer research community and provides advice to the NCI Director around approaches to enhance community input, optimize community outreach, and promote effective collaborations that will help address these challenges and lead to improved research outcomes. In addition, NCRA members bring their unique skills and perspectives by identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions. The NCRA focuses on enhancing community input, optimizing community outreach, and promoting strong collaborations to improve research outcomes.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$6,200.00Est Payments to Non-Fed Members Next FY*$6,200.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$43,295.00Estimated Payments to Federal Staff*$44,118.00
Payments to Consultants*$200.00Est. Payments to Consultants Next FY*$200.00
Travel Reimb. For Non-Federal Members*$19,014.00Est Travel Reimb Non-Fed Members nextFY*$19,118.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$2,078.00Est Travel Reimb to Consultants Next FY*$2,099.00
Other Costs$34,712.00Est. Other Costs Next FY*$35,060.00
Total Costs$105,499.00Est. Total Next FY*$106,795.00
Federal Staff Support (FTE)*0.30Est. Fed Staff Support Next FY*0.30
Hide Section - Custom Links

Custom Links

     Committee Level Reports               
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-001935National Cancer Institute Council of Research Advocates2017
 COM-002330National Cancer Institute Council of Research Advocates2016
 COM-004093National Cancer Institute Council of Research Advocates2015
 COM-004394National Cancer Institute Council of Research Advocates2014
 COM-005926National Cancer Institute Director's Consumer Liaison Group2013
 COM-006661National Cancer Institute Director's Consumer Liaison Group2012
 COM-007985National Cancer Institute Director's Consumer Liaison Group2011
 COM-008816National Cancer Institute Director's Consumer Liaison Group2010
 COM-010242National Cancer Institute Director's Consumer Liaison Group2009
 COM-010703National Cancer Institute Director's Consumer Liaison Group2008
 COM-011939National Cancer Institute Director's Consumer Liaison Group2007
 COM-012658National Cancer Institute Director's Consumer Liaison Group2006
 COM-014082National Cancer Institute Director's Consumer Liaison Group2005
 COM-014785National Cancer Institute Director's Consumer Liaison Group2004
 COM-015869National Cancer Institute Director's Consumer Liaison Group2003
 COM-016739National Cancer Institute Director's Consumer Liaison Group2002
 COM-017877National Cancer Institute Director's Consumer Liaison Group2001
 COM-018431National Cancer Institute Director's Consumer Liaison Group2000
 COM-019771National Cancer Institute Director's Consumer Liaison Group1999
 COM-020460National Cancer Institute Director's Consumer Liaison Group1998
 COM-034638National Cancer Institute Council of Research Advocates2018